Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders
Publication date
2021-08
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
Fibrosis is a common denominator in many pathologies and crucially affects disease progression, drug delivery efficiency and therapy outcome. We here summarize therapeutic and diagnostic strategies for fibrosis targeting in atherosclerosis and cardiac disease, cancer, diabetes, liver diseases and viral infections. We address various anti-fibrotic targets, ranging from cells and genes to metabolites and proteins, primarily focusing on fibrosis-promoting features that are conserved among the different diseases. We discuss how anti-fibrotic therapies have progressed over the years, and how nanomedicine formulations can potentiate anti-fibrotic treatment efficacy. From a diagnostic point of view, we discuss how medical imaging can be employed to facilitate the diagnosis, staging and treatment monitoring of fibrotic disorders. Altogether, this comprehensive overview serves as a basis for developing individualized and improved treatment strategies for patients suffering from fibrosis-associated pathologies.
Keywords
Fibrosis, Drug targeting, Nanomedicine, Imaging, Atherosclerosis, Cardiovascular disease, Cancer, Diabetes, Liver, Viral infection, Taverne, SDG 3 - Good Health and Well-being
Citation
Sofias, A M, De Lorenzi, F, Peña, Q, Azadkhah Shalmani, A, Vucur, M, Wang, J-W, Kiessling, F, Shi, Y, Consolino, L, Storm, G & Lammers, T 2021, 'Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders', Advanced Drug Delivery Reviews, vol. 175, 113831, pp. 1-36. https://doi.org/10.1016/j.addr.2021.113831